Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Research
| Technology Name (St. Jude Reference #) |
Treatment of Ocular Cancers with p53 Activators (SJ-06-0004 016) |
| Description | Treatment of ocular cancers, such as retinoblastoma, using activators of the p53 pathway is provided. Compounds which inhibit the effect of MDM2 and MDMX on p53, such as nutlin-3, are identified as useful for activating p53 and treating ocular cancers. |
| Keywords | MDMX, MDM2, p53, retinoblastoma, nutlin |
| Granted Patents or Published Applications | Pending U.S. Patent Appln.published Dec. 3, 2009 as Pub. No. 2009/0298785 |
| Related Scientific References | Laurie, N.A. et al., “Targeting MDM2 and MDMX in retinoblastoma”, Curr. Cancer Drug Targets 7(7): 689-695 (2007); Marine, J.C. et al., “MDMX: from bench to bedside”, J. Cell Science 120(Pt3): 371-378 (2007); Laurie, N.A. et al., “Inactivation of the p53 pathway in retinoblastoma”, Nature 444(7115): 61-66 (2006). |
| Licensing Opportunities | We are currently seeking licensing opportunities in all fields for the development of this technology. |
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.
Last update: September 2010
